Nuclear S100A7 is associated with poor prognosis in head and neck cancer
Satyendra Chandra Tripathi, Ajay Matta, Jatinder Kaur, Jorg Grigull, Shyam Singh Chauhan, Alok Thakar, Nootan Kumar Shukla, Ritu Duggal, Siddhartha DattaGupta, Ranju Ralhan, K W Michael Siu, Satyendra Chandra Tripathi, Ajay Matta, Jatinder Kaur, Jorg Grigull, Shyam Singh Chauhan, Alok Thakar, Nootan Kumar Shukla, Ritu Duggal, Siddhartha DattaGupta, Ranju Ralhan, K W Michael Siu
Abstract
Background: Tissue proteomic analysis of head and neck squamous cell carcinoma (HNSCC) and normal oral mucosa using iTRAQ (isobaric tag for relative and absolute quantitation) labeling and liquid chromatography-mass spectrometry, led to the identification of a panel of biomarkers including S100A7. In the multi-step process of head and neck tumorigenesis, the presence of dysplastic areas in the epithelium is proposed to be associated with a likely progression to cancer; however there are no established biomarkers to predict their potential of malignant transformation. This study aimed to determine the clinical significance of S100A7 overexpression in HNSCC.
Methodology: Immunohistochemical analysis of S100A7 expression in HNSCC (100 cases), oral lesions (166 cases) and 100 histologically normal tissues was carried out and correlated with clinicopathological parameters and disease prognosis over 7 years for HNSCC patients. Overexpression of S100A7 protein was significant in oral lesions (squamous cell hyperplasia/dysplasia) and sustained in HNSCC in comparison with oral normal mucosa (p(trend)<0.001). Significant increase in nuclear S100A7 was observed in HNSCC as compared to dysplastic lesions (p = 0.005) and associated with well differentiated squamous cell carcinoma (p = 0.031). Notably, nuclear accumulation of S100A7 also emerged as an independent predictor of reduced disease free survival (p = 0.006, Hazard ratio (HR = 7.6), 95% CI = 1.3-5.1) in multivariate analysis underscoring its relevance as a poor prognosticator of HNSCC patients.
Conclusions: Our study demonstrated nuclear accumulation of S100A7 may serve as predictor of poor prognosis in HNSCC patients. Further, increased nuclear accumulation of S100A7 in HNSCC as compared to dysplastic lesions warrants a large-scale longitudinal study of patients with dysplasia to evaluate its potential as a determinant of increased risk of transformation of oral premalignant lesions.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249.
- Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer. 2005;5:127–135.
- Warnakulasuriya KA, Ralhan R. Clinical, pathological, cellular and molecular lesions caused by oral smokeless tobacco—a review. J Oral Pathol Med. 2007;36:63–77.
- Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36:575–580.
- Bettendorf O, Piffko J, Bankfalvi A. Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy? Oral Oncol. 2004;40:110–119.
- Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin. 2002;52:195–215.
- Ralhan R, Desouza LV, Matta A, Chandra Tripathi S, Ghanny S, et al. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics. 2008;7:1162–1173.
- Ralhan R, Desouza LV, Matta A, Chandra Tripathi S, Ghanny S, et al. iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J Proteome Res. 2009;8:300–309.
- Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J. 2006;396:201–214.
- Mueller A, Schafer BW, Ferrari S, Weibel M, Makek M, et al. The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. J Biol Chem. 2005;280:29186–29193.
- Watson PH, Leygue ER, Murphy LC. Psoriasin (S100A7). Int J Biochem Cell Biol. 1998;30:567–571.
- Emberley ED, Murphy LC, Watson PH. S100A7 and the progression of breast cancer. Breast Cancer Res. 2004;6:153–159.
- Heizmann CW, Fritz G, Schafer BW. S100 proteins: structure, functions and pathology. Front Biosci. 2002;7:d1356–1368.
- Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech. 2003;60:540–551.
- Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001;33:637–668.
- Eckert RL, Broome AM, Ruse M, Robinson N, Ryan D, et al. S100 proteins in the epidermis. J Invest Dermatol. 2004;123:23–33.
- Madsen P, Rasmussen HH, Leffers H, Honore B, Dejgaard K, et al. Molecular cloning, occurrence, and expression of a novel partially secreted protein “soriasin”that is highly up-regulated in psoriatic skin. J Invest Dermatol. 1991;97:701–712.
- Broome AM, Ryan D, Eckert RL. S100 protein subcellular localization during epidermal differentiation and psoriasis. J Histochem Cytochem. 2003;51:675–685.
- El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res. 2002;62:6823–6826.
- Zhang H, Zhao Q, Chen Y, Wang Y, Gao S, et al. Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. Thorax. 2008;63:352–359.
- Moubayed N, Weichenthal M, Harder J, Wandel E, Sticherling M, et al. Psoriasin (S100A7) is significantly up-regulated in human epithelial skin tumours. J Cancer Res Clin Oncol. 2007;133:253–261.
- Ji J, Zhao L, Wang X, Zhou C, Ding F, et al. Differential expression of S100 gene family in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2004;130:480–486.
- Celis JE, Rasmussen HH, Vorum H, Madsen P, Honore B, et al. Bladder squamous cell carcinomas express psoriasin and externalize it to the urine. J Urol. 1996;155:2105–2112.
- Al-Haddad S, Zhang Z, Leygue E, Snell L, Huang A, et al. Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol. 1999;155:2057–2066.
- Sapkota D, Bruland O, Boe OE, Bakeer H, Elgindi OA, et al. Expression profile of the S100 gene family members in oral squamous cell carcinomas. J Oral Pathol Med. 2008;37:607–615.
- Moriyama-Kita M, Endo Y, Yonemura Y, Heizmann CW, Schafer BW, et al. Correlation of S100A4 expression with invasion and metastasis in oral squamous cell carcinoma. Oral Oncol. 2004;40:496–500.
- Tsai ST, Jin YT, Tsai WC, Wang ST, Lin YC, et al. S100A2, a potential marker for early recurrence in early-stage oral cancer. Oral Oncol. 2005;41:349–357.
- Suzuki F, Oridate N, Homma A, Nakamaru Y, Nagahashi T, et al. S100A2 expression as a predictive marker for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral cavity. Oncol Rep. 2005;14:1493–1498.
- Kesting MR, Sudhoff H, Hasler RJ, Nieberler M, Pautke C, et al. Psoriasin (S100A7) up-regulation in oral squamous cell carcinoma and its relation to clinicopathologic features. Oral Oncol. 2009;45:731–736.
- Zhou G, Xie TX, Zhao M, Jasser SA, Younes MN, et al. Reciprocal negative regulation between S100A7/psoriasin and beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity. Oncogene. 2008;27:3527–3538.
- Anderson KS, Wong J, Polyak K, Aronzon D, Enerback C. Detection of psoriasin/S100A7 in the sera of patients with psoriasis. Br J Dermatol. 2009;160:325–332.
- Leon R, Murray JI, Cragg G, Farnell B, West NR, et al. Identification and characterization of binding sites on S100A7, a participant in cancer and inflammation pathways. Biochemistry. 2009;48:10591–10600.
- Webb M, Emberley ED, Lizardo M, Alowami S, Qing G, et al. Expression analysis of the mouse S100A7/psoriasin gene in skin inflammation and mammary tumorigenesis. BMC Cancer. 2005;5:17.
- Banerjee AG, Bhattacharyya I, Vishwanatha JK. Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia. Mol Cancer Ther. 2005;4:865–875.
- Jinquan T, Vorum H, Larsen CG, Madsen P, Rasmussen HH, et al. Psoriasin: a novel chemotactic protein. J Invest Dermatol. 1996;107:5–10.
- Gazel A, Rosdy M, Bertino B, Tornier C, Sahuc F, et al. A characteristic subset of psoriasis-associated genes is induced by oncostatin-M in reconstituted epidermis. J Invest Dermatol. 2006;126:2647–2657.
- Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203:2271–2279.
- West NR, Watson PH. S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer. Oncogene. 29:2083–2092.
- Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2008;113:750–757.
- Kaur J, Sawhney M, Dattagupta S, Shukla NK, Srivastava A, et al. Clinical significance of Phosphatidyl Inositol Synthase overexpression in oral cancer. BMC Cancer. 2010;10:168.
- Emberley ED, Niu Y, Njue C, Kliewer EV, Murphy LC, et al. Psoriasin (S100A7) expression is associated with poor outcome in estrogen receptor-negative invasive breast cancer. Clin Cancer Res. 2003;9:2627–2631.
- Enerback C, Porter DA, Seth P, Sgroi D, Gaudet J, et al. Psoriasin expression in mammary epithelial cells in vitro and in vivo. Cancer Res. 2002;62:43–47.
- Leygue E, Snell L, Hiller T, Dotzlaw H, Hole K, et al. Differential expression of psoriasin messenger RNA between in situ and invasive human breast carcinoma. Cancer Res. 1996;56:4606–4609.
- Celis JE, Moreira JM, Gromova I, Cabezon T, Gromov P, et al. Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. Mol Oncol. 2007;1:97–119.
- Jiang WG, Watkins G, Douglas-Jones A, Mansel RE. Psoriasin is aberrantly expressed in human breast cancer and is related to clinical outcomes. Int J Oncol. 2004;25:81–85.
- Moriyama-Kita M, Endo Y, Yonemura Y, Heizmann CW, Miyamori H, et al. S100A4 regulates E-cadherin expression in oral squamous cell carcinoma. Cancer Lett. 2005;230:211–218.
- Wang D, Li Z, Messing EM, Wu G. Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM. J Biol Chem. 2002;277:36216–36222.
- Zhang H, Wang Y, Chen Y, Sun S, Li N, et al. Identification and validation of S100A7 associated with lung squamous cell carcinoma metastasis to brain. Lung Cancer. 2007;57:37–45.
- Uma RS, Naresh KN, D'Cruz AK, Mulherkar R, Borges AM. Metastasis of squamous cell carcinoma of the oral tongue is associated with down-regulation of epidermal fatty acid binding protein (E-FABP). Oral Oncol. 2007;43:27–32.
- Matta A, Tripathi SC, DeSouza LV, Grigull J, Kaur J, et al. Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. Int J Cancer. 2009;125:1398–1406.
- Matta A, DeSouza LV, Shukla NK, Gupta SD, Ralhan R, et al. Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry. J Proteome Res. 2008;7:2078–2087.
- Arora S, Matta A, Shukla NK, Deo SV, Ralhan R. Identification of differentially expressed genes in oral squamous cell carcinoma. Mol Carcinog. 2005;42:97–108.
Source: PubMed